RXRX logo

Recursion Pharmaceuticals Inc. (RXRX)

$2.72

Quotes are delayed by 15 minutes.

1D

1W

1M

3M

6M

YTD

1Y

2Y

5Y

ALL

Key data on RXRX

Market cap

$1.69B

EPS

-0.86

P/E ratio

--

Price to sales

43.27

Dividend yield

--

Beta

1.147788

Price on RXRX

Previous close

$2.91

Today's open

$2.95

Day's range

$2.50 - $2.95

52 week range

$2.50 - $5.24

Profile about RXRX

CEO

Najat Khan

Employees

600

Headquarters

Salt Lake City, UT

Exchange

Nasdaq Global Select

Shares outstanding

622759259

Issue type

Common Stock

RXRX industries and sectors

Healthcare

Biotechnology & Life Sciences

News on RXRX

Why Recursion Pharmaceuticals Stock Is Up Today

One of Recursion Pharmaceuticals' internally developed drugs is advancing to late-stage clinical trials. While only aiming at a relatively small opportunity, Wednesday's announcement affirms the value of Recursion's AI-powered pre-clinical-testing solution.

news source

The Motley Fool • 7 hours ago

news preview

Stock Market Today, Nov. 18: Recursion Pharmaceuticals Rises 4% on FDA Alignment for REC-4881 Phase 3 Design

On Nov. 18, 2026, Recursion shares climbed after regulators aligned on its lead familial adenomatous polyposis trial, though investors are watching for more detail.

news source

The Motley Fool • 2 hours ago

news preview

Recursion Announces Alignment with FDA on Registrational Phase 3 Trial Design for REC-4881 in Familial Adenomatous Polyposis

REC-4881 is among the first AI-enabled programs to advance a registrational Phase 3 trial design for a disease with no approved pharmacologic therapies. Its potential as a first-in-class oral therapy for FAP was identified through unbiased phenotypic screening using Recursion's AI foundation models.

news source

GlobeNewsWire • 14 hours ago

news preview

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, UT, Nov. 11, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today announced its participation in the following upcoming investor conferences: Jefferies Global Healthcare Conference London — Wednesday, November 18, 2026 Evercore 9th Annual Healthcare Conference — Monday, November 30, 2026 Citi's 2026 Global Healthcare Conference — Tuesday, December 1, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com .  About Recursion Recursion (Nasdaq: RXRX) is a leading clinical-stage company pioneering AI-enabled drug discovery and development decoding biology to radically improve lives.

news source

GlobeNewsWire • Nov 11, 2026

news preview

2 healthcare stocks to turn $10 into $100 by next year

Healthcare stocks have emerged as an area of relative strength in 2026, outperforming technology shares as investors seek opportunities beyond the artificial intelligence (AI) boom.

news source

Finbold • Nov 11, 2026

news preview

RXRX Q3 Earnings Call Highlights Clinical Progress and Cash Runway

Recursion highlights promising clinical data for REC-4881 and REC-1245, beats Q3 earnings estimates and extends its cash runway into 2029 through disciplined spending.

news source

Zacks Investment Research • Nov 4, 2026

news preview

What Recursion Pharmaceuticals (RXRX) Said on Its Q3 Earnings Call

Recursion Pharmaceuticals NASDAQ: RXRX reported updated clinical data for its investigational treatment for familial adenomatous polyposis, or FAP, along with early activity in its solid-tumor program REC-1245, partnership progress and an extension of its expected cash runway into 2029.

news source

MarketBeat • Nov 3, 2026

news preview

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2026 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. ( RXRX ) Q3 2026 Earnings Call November 3, 2026 8:00 AM EST Company Participants Najat Khan - CEO, President & Director Vicki Goodman - Chief Medical Officer Ben Taylor - CFO & President of Recursion UK Conference Call Participants Evelien Dekker Bryson Katona Jesse Laster Lindsay Huff Laura Laster Presentation Najat Khan CEO, President & Director Good morning, everyone, and thank you for joining Recursion's Third Quarter Earnings Call. We're hosting earnings live from the CGA-IGC Annual Meeting in Denver.

news source

Seeking Alpha • Nov 3, 2026

news preview

Recursion's Q3 Earnings Beat Estimates on Sanofi Milestone Revenues

RXRX Q3 revenues surge 258.5%, beating estimates as a $10 million Sanofi milestone payment boosts results and advances its drug pipeline.

news source

Zacks Investment Research • Nov 3, 2026

news preview

Recursion Reports Third Quarter 2026 Financial Results and Extends Cash Runway; Highlights Positive Clinical Data in REC-4881 and REC-1245, Sanofi Development Candidate Option and Appointment of Fred Hassan as Chair

SALT LAKE CITY, Nov. 02, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical-stage company pioneering AI-enabled drug discovery and development, today reported financial results for the third quarter ended September 30, 2026, together with business updates highlighting continued clinical, pipeline and platform execution.

news source

GlobeNewsWire • Nov 2, 2026

news preview

¹ Disclosures

Get started with M1

Invest in Recursion Pharmaceuticals Inc.

Open an M1 investment account to buy and sell Recursion Pharmaceuticals Inc. commission-free¹. Build wealth for the long term using automated trading and transfers.

Invest in RXRX on M1